The Evidence

What the clinical data actually says.

No marketing copy. No testimonials. Just the peer-reviewed research that should inform your decision. Every claim links to its source.

How GLP-1 Agonists Work

GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces after eating. It signals satiety, slows gastric emptying, and stimulates insulin release. GLP-1 receptor agonists like semaglutide mimic this hormone — but last much longer in the body (days vs. minutes).

What makes these medications remarkable isn't just the weight loss — it's whereGLP-1 receptors exist. They're found in the brain (appetite regulation, neuroprotection), heart (cardioprotection), liver (fat metabolism), kidneys (filtration), and gut (motility).

This widespread receptor distribution is why researchers are finding benefits far beyond weight management — and why understanding the full picture matters before starting.

Weight Management — The Primary Evidence

STEP 1

Wilding JPH, et al. N Engl J Med. 2021;384:989-1002
Drug: Semaglutide 2.4mg weekly
N: 1,961
Duration: 68 weeks

14.9% body weight reduction (vs 2.4% placebo)

  • -86.4% of participants lost ≥5% body weight
  • -69.1% lost ≥10% body weight
  • -50.5% lost ≥15% body weight
  • -Improvements in cardiometabolic risk factors across the board

STEP 5

Garvey WT, et al. Nat Med. 2022;28:2083-2091
Drug: Semaglutide 2.4mg weekly (long-term)
N: 304
Duration: 104 weeks (2 years)

15.2% sustained weight loss at 2 years

  • -Weight loss maintained with continued treatment
  • -Improvements in waist circumference, blood pressure, lipids sustained
  • -Key insight: this requires ongoing use — it's a treatment, not a cure

SURMOUNT-1

Jastreboff AM, et al. N Engl J Med. 2022;387:205-216
Drug: Tirzepatide (dual GIP/GLP-1)
N: 2,539
Duration: 72 weeks

Up to 22.5% weight loss at 15mg dose

  • -5mg: 15.0% weight loss
  • -10mg: 19.5% weight loss
  • -15mg: 22.5% weight loss
  • -Dose-dependent response allows personalized titration
  • -Dual mechanism (GIP + GLP-1) may explain enhanced efficacy

Beyond Weight Loss — Emerging Evidence

This is where it gets interesting. GLP-1 agonists are showing benefits that have nothing to do with the number on a scale.

SELECT Trial

Lincoff AM, et al. N Engl J Med. 2023;389:2221-2232
Drug: Semaglutide 2.4mg weekly
N: 17,604
Duration: 33 months (median)

20% reduction in major adverse cardiovascular events

  • -First obesity drug to show cardiovascular event reduction
  • -Benefit independent of baseline diabetes status
  • -Reduced cardiovascular death, non-fatal MI, non-fatal stroke
  • -This changed the paradigm — it's not just about weight

Anti-Inflammatory Effects

  • -CRP (C-reactive protein) reduced by 35-40% in STEP trials — independent of weight loss
  • -Reduced inflammatory cytokines (IL-6, TNF-α) in multiple studies
  • -GLP-1 receptors on immune cells suggest direct anti-inflammatory action
  • -Potential implications for chronic inflammatory conditions

Verma S, et al. Eur Heart J. 2024;45:1571-1581

Drucker DJ. Cell Metab. 2024;36:781-800

Neurological & Cognitive

  • -GLP-1 receptors present throughout the brain — hippocampus, cortex, hypothalamus
  • -Phase 2 trials showing potential in Alzheimer's disease (liraglutide)
  • -Reduced neuroinflammation markers in preclinical models
  • -Ongoing Phase 3 trials for Parkinson's disease (exenatide)
  • -Mechanism: reduced oxidative stress, enhanced neuronal survival signals

Femminella GD, et al. Alzheimers Res Ther. 2019;11:44

Athauda D, et al. Lancet. 2017;390:1664-1675

Liver & Metabolic Health

  • -Significant reduction in liver fat content (NAFLD/NASH)
  • -Semaglutide showed histological improvement in NASH in Phase 2
  • -Reduced liver fibrosis markers
  • -Improved insulin sensitivity independent of weight loss

Newsome PN, et al. N Engl J Med. 2021;384:1113-1124

Loomba R, et al. N Engl J Med. 2024;391:311-319

Kidney Protection

  • -FLOW trial: 24% reduction in kidney disease progression (semaglutide)
  • -Reduced albuminuria (protein in urine — marker of kidney damage)
  • -Benefits seen in patients with and without diabetes
  • -Trial stopped early due to overwhelming efficacy

Perkovic V, et al. N Engl J Med. 2024;391:109-121

Addiction & Compulsive Behavior

  • -Observational data showing reduced alcohol consumption
  • -Emerging evidence for reduced compulsive eating patterns
  • -GLP-1 receptors in reward circuitry (nucleus accumbens, VTA)
  • -Active clinical trials for alcohol use disorder
  • -Early-stage but biologically plausible mechanism

Wang W, et al. J Clin Invest. 2024;134:e173183

Klausen MK, et al. JCI Insight. 2022;7:e159863

What they don't tell you

Weight regain after stopping

The STEP 1 extension trial showed approximately 2/3 of weight lost was regained within 1 year of discontinuation. This isn't a 'course of treatment' you complete — for most people, sustained benefit requires sustained use. Know this going in.

Wilding JPH, et al. Diabetes Obes Metab. 2022;24:1553-1564

Muscle loss is real

25-40% of weight lost on GLP-1 agonists is lean mass (muscle), not just fat. This matters especially at higher doses and without resistance training. A responsible protocol includes strength training guidance — not just a prescription.

Ida S, et al. J Diabetes Investig. 2021;12:2050-2061

GI side effects are common

In STEP trials, 44% experienced nausea, 24% diarrhea, 24% constipation, 24% vomiting. These are dose-dependent and usually resolve in 4-8 weeks — but 'usually' isn't 'always.' Starting low and titrating slowly helps significantly.

STEP 1-4 pooled safety data, Novo Nordisk

Long-term unknowns

These medications have been used for diabetes since 2017, for obesity since 2021. That's meaningful safety data — but it's not 30-year data. Thyroid C-cell tumors were seen in rodent studies (not confirmed in humans). Transparency means acknowledging what we don't yet know.

FDA Prescribing Information, Wegovy (semaglutide)

The Bottom Line

GLP-1 agonists are the most effective pharmacological weight loss intervention ever developed. They also show remarkable benefits for cardiovascular health, inflammation, liver disease, and potentially neurodegeneration.

They are not magic. They require ongoing use for sustained effect. They cause side effects, especially during titration. They work best as part of a complete approach including nutrition and exercise.

If you understand all of this and want to explore whether GLP-1 therapy is right for you — at a dose matched to your specific goals — we can connect you with a licensed physician.

Start your assessment